Emergence of the same few mutations simultaneously in different parts of the world gives scientists cautious optimism that there may be limits on the pandemic's endurance.
For Kate Kelland's latest contributions to The Japan Times, see below:
Vaccine breakthroughs had initially sparked hope that the virus could be largely contained, but data on new variants has undercut that optimism.
A review of records and interviews with scientists and industry figures gives a detailed account of what went wrong with the Oxford-AstraZeneca study.
A Lancet study gave few extra clues about why efficacy was 62% for trial participants given two full doses, but 90% for a smaller subgroup given a half, then a full dose.
Some employees are coming under heavy pressure to sign up for the trials, an effort that medical ethicists say may run afoul of ethical norms.
The two partners have given conflicting accounts of how they came upon the most effective dosing pattern for their COVID-19 vaccine.
The Oxford vaccinologists were exhilarated on Monday when drugmaker AstraZeneca, with whom they developed the shot, announced that it could be around 90% effective.
Figuring out what's needed to achieve herd immunity with COVID-19 vaccines involves a range of factors, several of which are unknown.
The internal debate over the WHO’s messaging around China provides a window into the challenges facing the 72-year-old U.N. organization and its leader.
Cutting back on red and processed meat brings few if any health benefits, according to a review of studies involving millions of people, a finding that contradicts dietary advice of leading international agencies and raised immediate objections from many health experts. Most people can continue ...